Amarin Corp Plcuk (AMRN) EBITDA Margin Growth (1y) (2014 - 2026)
Amarin Corp Plcuk (AMRN) EBITDA Margin Growth (1y) (2014 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBITDA Margin Growth (1y) (Qtr) |
| 1 |
Gsk |
92,316,836.42 Bn |
92,316,831.46 Bn |
7.76 Bn |
57.00 |
| 2 |
Eli Lilly |
983.57 Bn |
978.29 Bn |
16.22 Bn |
660.00 |
| 3 |
Johnson & Johnson |
553.56 Bn |
531.50 Bn |
15.96 Bn |
-179.00 |
| 4 |
AbbVie |
383.35 Bn |
374.00 Bn |
10.78 Bn |
-138.00 |
| 5 |
Merck |
281.71 Bn |
276.06 Bn |
12.09 Bn |
-6,345.00 |
| 6 |
Amgen |
182.20 Bn |
170.16 Bn |
5.87 Bn |
1,648.00 |
| 7 |
Gilead Sciences |
153.71 Bn |
145.98 Bn |
5.52 Bn |
360.00 |
| 8 |
Pfizer |
143.75 Bn |
130.98 Bn |
-1.21 Bn |
2,760.00 |
| 9 |
Bristol Myers Squibb |
109.71 Bn |
99.25 Bn |
8.07 Bn |
437.00 |
| 10 |
Amarin Corp Plcuk |
6.77 Bn |
6.59 Bn |
17.77 Mn |
1,476.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
1,476.00 |
| Dec 31, 2025 |
3,871.00 |
| Sep 30, 2025 |
3,715.00 |
| Jun 30, 2025 |
-2,120.00 |
| Mar 31, 2025 |
-1,584.00 |
| Dec 31, 2024 |
-3,397.00 |
| Sep 30, 2024 |
-2,703.00 |
| Jun 30, 2024 |
2,911.00 |
| Mar 31, 2024 |
-386.00 |
| Dec 31, 2023 |
7,665.00 |
| Sep 30, 2023 |
-2,675.00 |
| Jun 30, 2023 |
3,664.00 |
| Mar 31, 2023 |
974.00 |
| Dec 31, 2022 |
-1,647.00 |
| Sep 30, 2022 |
348.00 |
| Jun 30, 2022 |
-7,221.00 |
| Mar 31, 2022 |
-2,898.00 |
| Dec 31, 2021 |
157.00 |
| Sep 30, 2021 |
-477.00 |
| Jun 30, 2021 |
261.00 |
